Search - tctmd.com

Displaying 1 - 20 of 68

Sort: Relevancy | Date

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

News Conference News ESC Heart Failure 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

May 20, 2025

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

News Daily News

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

April 15, 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

Some Mitral TEER Patients Slipping Through the Cracks in the First Month

News Daily News

Some Mitral TEER Patients Slipping Through the Cracks in the First Month

Michael O'Riordan

March 21, 2025

Patient-Centric Outcomes Embraced by Global Heart Valve Experts

News Daily News

Patient-Centric Outcomes Embraced by Global Heart Valve Experts

February 24, 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

News Conference News THT 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

February 19, 2025

HF Benefits Look Durable in Single-Arm Study of Coronary Sinus Shunt

News Conference News THT 2025

HF Benefits Look Durable in Single-Arm Study of Coronary Sinus Shunt

February 18, 2025

Evidence That Challenges the Validity of KCCQ as a Measure of Quality of Life in Both Blinded and Unblinded Studies

Presentation THT 2025

Evidence That Challenges the Validity of KCCQ as a Measure of Quality of Life in Both Blinded and Unblinded Studies

Presenter: Gregg Stone

February 13, 2025

Evidence Supporting the Use of KCCQ as a Valid Measure of Quality of Life in Both Blinded and Unblinded Studies

Presentation THT 2025

Evidence Supporting the Use of KCCQ as a Valid Measure of Quality of Life in Both Blinded and Unblinded Studies

Presenter: David Cohen

February 13, 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

February 12, 2025

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

News Conference News ESC 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

August 31, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

News Daily News

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results

Yael L. Maxwell

August 01, 2024

Semaglutide Has Similar Benefits in Women and Men With HFpEF

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

June 26, 2024

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.